From Barcelona to Boston: MEDSIR Celebrates 13 Years Advancing Global Cancer Research Through Innovation and international Collaboration

• Over 2,600 patients, 600 researchers and more than 60 clinical trials: Born in Barcelona 13 years ago, MEDSIR’s model proves that independent clinical research in oncology can deliver global impact without compromising scientific freedom 

  
  

• As Giulia Raimondi, Strategic Research Development Chief of the company quotes “We’re more than a research platform –we're an international community where the sharpest minds in oncology come together to rethink what’s possible”   

Barcelona, April 22nd, 2025 – As MEDSIR celebrates its anniversary, the organization reflects on a track record that is redefining how independent oncology research is conducted, combining scientific excellence, international collaboration and operational agility to bring innovative solutions closer to professionals and patients.  

Since its founding in 2012 by breast cancer oncologists and key opinion leaders (KOLs) Javier Cortés and Antonio Llombart alongside Maria Campos, current CEO, MEDSIR has grown into a global player in investigator-initiated clinical trials. Headquartered in Barcelona and Boston, the organization is active across Europe, the Americas and Asia, and has played a key role to in ensuring that the most innovative ideas could be strategically developed and efficiently managed while meeting the highest industry quality standards.  

Over these 13 years, MEDSIR has collaborated with more than 600 researchers worldwide, supporting the development of oncology research concepts. This collective scientific creativity has led to the development of research projects and the execution of 65 clinical trials at more than 200 sites in 14 countries. 

“At MEDSIR, we don’t just support research—we create the conditions for bold, independent science to thrive,” says Giulia Raimondi, Strategic Research Development Chief of MEDSIR. “From the very beginning, our mission has been to streamline the path from concept to clinical trial, relying on a strong network of more than 600 talented researchers focused on real patient needs. Seeing more than 2,600 patients around the world taking part in our studies is the most powerful validation of that mission.” MEDSIR has proven that its model—based on scientific rigor, international collaboration, and operational agility—can attract major partners while delivering real-world impact. 

Throughout its journey, MEDSIR has maintained a strong commitment to scientific excellence. The company has produced 146 scientific outputs, including 52 peer-reviewed manuscripts and 94 presentations at major international congresses. Notably, 67% of its publications appear in Q1 journals such as The Lancet, Nature or Journal of Clinical Oncology (JCO), among others, reflecting the high impact and relevance of its work. 

“Our strength lies in our ability to connect the dots between great ideas, clinical needs, and efficient trial execution,” explains Raimondi. “By supporting investigators with an agile structure and global reach, we help turn promising concepts into solid data and potential treatments faster.” 

From its headquarters in Barcelona, MEDSIR has expanded into the United States including a second hub in Boston and, in 2022 Brazil, forming a key alliance with Oncoclínicas & Co—the largest oncology group in Latin America—to scale independent clinical research across continents. Its hybrid approach bridges the gap between investigator-led studies and the standards of pharma-driven trials, offering a unique path forward for innovation in cancer care. 

“MEDSIR is not only a catalyst for ideas; it’s a global platform where the best minds and companies in oncology come together to rethink what’s possible,” adds Giulia Raimondi. “As we celebrate these 13 years, we’re more committed than ever to pushing the boundaries of cancer research.” 

Looking ahead, MEDSIR remains focused on expanding its global reach, investing in disruptive solutions—including artificial intelligence and precision oncology—and championing research that addresses unmet needs connecting key stakeholders around the world alongside top Pharma and Biotech companies. Because at the heart of MEDSIR’s mission is a simple belief: innovation in cancer research should never be limited by borders.